Clinical Trials Search
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. The Phase1b part of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 part. The Phase 2 part of each sub-study will evaluate the anti-tumor activity of the combination.
Phase 1b Primary Objective: To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to recommend a RP2D for the combination. Phase 2 Primary Objective: To assess the durable ORR of sasanlimab in combination with encorafenib and binimetinib.
Binimetinib (); Encorafenib (); PF-06801591 (Sasanlimab); Sasanlimab ()